Start with STELARA®
for lasting remission IN CD*
Start with STELARA®
for lasting remission IN CD*
FOR ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CD
*In both the CD and UC studies, many patients achieved clinical remission at 1 year with STELARA®.
FAST
6-WEEK RAPID RESPONSE:
Many patients achieved clinical response† at Week 6 and 70-
point response as early as Week 3 in clinical studies1
LASTS
LASTING REMISSION:
Many patients achieved clinical remission‡ at 1 year in a
clinical study1
PROVEN
SAFETY PROFILE:
STELARA® has a proven safety profile through 1 year. Plus safety
data through 5 years (from Phase 3 studies and open-label LTE)1,2
Once the decision has been made to prescribe STELARA®
The Provider Portal is still available. There you can request and review benefits investigations, enroll eligible patients in the STELARA withMe Savings Program, and view Savings Program transactions as requested by the patient.
The patient support and resources provided by STELARA withMe are not intended to give medical advice, replace a treatment plan from the patient’s healthcare provider, offer services that would normally be performed by the provider’s office, or serve as a reason to prescribe STELARA®.
CD=Crohn’s disease; CDAI=Crohn’s Disease Activity Index; LTE=long-term extension; UC=ulcerative colitis.
†Clinical response was defined as reduction in CDAI score of ≥100 points or CDAI score of <150.
‡Clinical remission was defined as a CDAI score of <150.
References: 1. STELARA® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc. 2. Data on file. Janssen Biotech, Inc.
Need help?
Chat With Medical Information